

Date: 13/08/2022

To

Dept. of Corporate Services,
BSE Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.

Scrip code: 526445

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please refer our letter dated August 06, 2022 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In continuation, we wish to inform that at the meeting of Board of Directors held today i.e., on August 13, 2022, the Directors has inter-alia, amongst other subject approved the following:

- Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report of the Company for the quarter ended June 30, 2022 (Q1), pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We, herewith, have attached the copy of the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2022 along with the Limited Review Report for the said period.

The Board Meeting commenced at 3:45 p.m and concluded at 4:45 p.m. We are arranging to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website www.indrayani.com and also on BSE website www.bseindia.com.

We request you to kindly take the same on your records.

Thanking you.

Yours faithfully,

For Indrayani Biotech Limited



Vennila Vijayaragavan

Company Secretary & Compliance Officer



Encl: As above.



Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI(Listing Obligations and disclosure requirements) regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30th June, 2022** and for the period from **1st April 2022 to 30th June 2022** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **30th June, 2021** and corresponding period from 1st April 2021 to 30th June 2021 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the unaudited results of the following entities:

- i. HSL Agri Solutions Limited – Subsidiary
- ii. IBL Healthcare Limited – Subsidiary
- iii. Dindigul Farm Product Private Limited - Subsidiary
- iv. IBL Thiruvannamalai LLP _ Step down Subsidiary
- v. HSL Prime Properties Private Limited - Subsidiary

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.




VENKATESH & CO
Chartered Accountants

We did not review the financial statement / financial information of **4 Subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30th June, 2022 reflects total revenues of **Rs.1495.69 Lakhs**, , total comprehensive profit / (loss) of **Rs 57.30 Lakhs** for the period ended on that date in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **Rs.4.90 Lakhs**, total net profit / (Loss) after tax of **Rs.(2.78) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S


CA Dasaraty V
Partner
M.No.026336



Place: Chennai
Date: 13/08/2022
UDIN: 22026336AOYUJB8027

INDRAYANI BIOTECH LIMITED					
Regd. Office :					
Block 1 Module No.33, 3rd Floor,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,GUINDY					
CHENNAI - 600032					
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2022					
					Rs. In Lakhs
SR No	PARTICULARS	CONSOLIDATED			
		Quarter Ended			Year Ended
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	(a) Net Sales/Revenue from Operations	2,563.21	1,724.67	1,431.22	6,157.18
	(b) Other Income	39.39	0.54	2.56	22.08
	Total Income from Operations	2,602.61	1,725.21	1,433.78	6,179.26
2	Expenses				
	(a) Cost of Materials consumed	1,615.76	1,223.26	940.68	4,104.29
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-		
	(c) Employee benefits expenses	438.64	180.97	294.71	1,021.64
	(d) Finance Costs	96.95	43.55	32.24	187.97
	(e) Depreciation and amortisation expense	66.41	17.87	10.66	65.94
	(f) Other expenses	206.11	96.57	92.19	354.23
	Total Expenses	2,423.86	1,562.23	1,370.47	5,734.07
3	Total profit / (Loss) before exceptional items and tax	178.75	162.98	63.31	445.19
4	Exceptional Items		-		
	Add:Share of Profit In Associates		(0.85)	1.21	
5	Total profit / (Loss) before tax	178.75	162.13	64.51	445.19
6	Total profit / (Loss) before tax				
7	Tax Expenses	(0.16)	1.24	-	1.24
	Current Tax				
	Deferred Tax				
	Total Tax Expenses				
8	Net Profit Loss for the period from continuing operations	178.91	160.89	64.51	443.95
9	Profit (loss) from discontinued operations before tax				
10	Tax expense of discontinued operations				
11	Net profit (loss) from discontinued operation after tax				
12	Share of profit (loss) of associates and joint ventures accounted for using equity method				
13	Total profit (loss) for period	178.91	160.89	64.51	443.95



For INDRAYANI BIOTECH LIMITED

K. Anjan Kumar
Managing Director

14	Other comprehensive income net of taxes				
15	Total Comprehensive income for the period attributable to	178.91	160.89	64.51	443.95
	Comprehensive income for the period attributable to owners of parent	161.46	150.72	67.25	442.75
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests	17.44	10.17	(2.73)	1.20
16	Details of equity share capital				
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00
17	Details of debt securities				
	Paid-up debt capital				
	Face value of debt securities				
18	Reserves excluding revaluation reserve				
19	Debenture redemption reserve				
20	Earnings per share				
i	Earnings per equity share for continuing operations	0.52	0.47	0.20	1.30
	Basic earnings (loss) per share from continuing operations	0.52	0.47	0.20	1.30
	Diluted earnings (loss) per share from continuing operations				
ii	Earnings per equity share for discontinued operations				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	Earnings per equity share				
	Basic earnings (loss) per share from continuing and discontinued operations	0.52	0.47	0.20	1.30
	Diluted earnings (loss) per share from continuing and discontinued operations	0.52	0.47	0.20	1.30

Notes:

1. The above Consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 13th August 2022 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).

3. Figures for three months ended 31 March 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.

4. There were no investor complaints pending at the beginning or at the end of the quarter.

5. Previous period figures have been regrouped wherever necessary.

Date : 13/08/2022

Place : Chennai



For INDRAYANI BIOTECH LIMITED

K. Jagan Mohan
Managing Director



VENKATESH & CO
Chartered Accountants

Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


**Review Report to the Board of Directors,
Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended June 2022. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For Venkatesh & Co
Chartered Accountants
F.R.No.004636S


CA Dasaraty V
Partner
M.No.026336



Place: Chennai
Date: 13th August 2022.
UDIN: 22026336AOYTBM5506

<p style="text-align: center;">INDRAYANI BIOTECH LIMITED Regd. Office : Block 1 Module No.33, 3rd Floor,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,GUINDY CHENNAI - 600032</p>				
SR No	STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2022			
	Rs. In Lakhs			
	PARTICULARS	STANDALONE		
		Quarter Ended		Year Ended
		30-Jun-22 Unaudited	31-Mar-22 Audited	30-Jun-21 Unaudited 31-Mar-22 Audited
1	Income from Operations			
	(a) Net Sales/Revenue from Operations	1,559.80	1,480.15	1,424.40 5,798.85
	(b) Other Income	38.24	0.57	2.53 22.08
	Total Income from Operations	1,598.04	1,480.72	1,426.93 5,820.94
2	Expenses			
	(a) Cost of Materials consumed	966.33	1,102.83	940.59 3,971.31
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade			
	(c) Employee benefits expenses	344.35	129.52	279.22 897.29
	(d) Finance Costs	39.03	43.55	32.24 187.97
	(e) Depreciation and amortisation expense	11.67	8.70	8.41 34.43
	(f) Other expenses	112.43	80.84	87.10 307.38
	Total Expenses	1,473.81	1,365.45	1,347.56 5,398.38
3	Total profit / (Loss) before exceptional items and tax	124.23	115.27	79.37 422.56
4	Exceptional Items			
	Add:Share of Profit In Associates			
5	Total profit / (Loss) before tax	124.23	115.27	79.37 422.56
6	Total profit / (Loss) before tax			
7	Tax Expenses			
	Current Tax			
	Deferred Tax			
	Total Tax Expenses			
8	Net Profit Loss for the period from continuing operations	124.23	115.27	79.37 422.56
9	Profit (loss) from discontinued operations before tax			
10	Tax expense of discontinued operations			
11	Net profit (loss) from discontinued operation after tax			
12	Share of profit (loss) of associates and joint ventures accounted for using equity method			
13	Total profit (loss) for period	124.23	115.27	79.37 422.56
14	Other comprehensive income net of taxes			
15	Total Comprehensive income for the period attributable to	124.23	115.27	79.37 422.56
	Comprehensive income for the period attributable to owners of parent	124.23	115.27	79.37 422.56
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			



For INDRAYANI BIOTECH LIMITED

K. Anjan Kumar
 Managing Director

16	Details of equity share capital				
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00
17	Details of debt securities				
	Paid-up debt capital				
	Face value of debt securities				
18	Reserves excluding revaluation reserve				
19	Debenture redemption reserve				
20	Earnings per share				
i	Earnings per equity share for continuing operations	0.36	0.34	0.23	1.23
	Basic earnings (loss) per share from continuing operations	0.36	0.34	0.23	1.23
	Diluted earnings (loss) per share from continuing operations				
ii	Earnings per equity share for discontinued operations				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	Earnings per equity share				
	Basic earnings (loss) per share from continuing and discontinued operations	0.36	0.34	0.23	1.23
	Diluted earnings (loss) per share from continuing and discontinued operations	0.36	0.34	0.23	1.23

Notes:

- 1.The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 13th August 2022 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- 2.The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- 3.Figures for three months ended 31 March 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.
4. There were no investor complaints pending at the beginning or at the end of the quarter.
5. Previous period figures have been regrouped wherever necessary.

Date : 13/08/2022

Place : Chennai



For INDRAYANI BIOTECH LIMITED

K. Jayaraj
Managing Director